Market Overview

Bristol-Myers Up Big After Drug Study Stopped Early

Bristol-Myers Up Big After Drug Study Stopped Early
Related BMY
Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers
These Were The Most Popular Buys And Sells Among Retail Investors In June
Home Federal Bank Of Tennessee Buys McDonald's Corp, Sells Bristol-Myers Squibb Company (GuruFocus)

Bristol-Myers Squibb Co (NYSE: BMY) was more than 3 percent higher in early trading after the company announced that Phase III study of Opdivo was stopped early after the trial "met its endpoint," according to a press release from the company. Opdivo "demonstrated superior overall survival" in patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Opdivo received approval from the U.S. Food and Drug Administration as a monotherapy in two cancer indications. Bristol-Myers said that patients in the trial will have the opportunity to continue or start treatment with Opdivo.

Bristol-Myers was 2.7 percent higher at last trade of $65.40. The stock has gained 11 percent this year and 32 percent over the prior 52 weeks. The company is still below its all-time peak around $80 per share hit in 1999.

Posted-In: bristol-myers squibbBiotech News FDA Movers General Best of Benzinga


Related Articles (BMY)

View Comments and Join the Discussion!